Menveo
Menveo is a quadrivalent meningococcal conjugate vaccine that protects against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The vaccine contains purified polysaccharides from these serogroups conjugated to CRM197, a non-toxic mutant of diphtheria toxin, to enhance the immune response.
Developed by Novartis Vaccines and Vaccines, Menveo is marketed by GlaxoSmithKline (GSK) following the company’s acquisition
Administration is by a single 0.5 mL intramuscular injection. Depending on national guidelines, a booster dose
Safety and efficacy: protection is assessed by serogroup-specific bactericidal antibodies, with effectiveness varying by population and